在前列腺活检后的排泄功能障碍中,外科阿尔法阻塞剂:元分析
Sean Lim1, Kylie Yen-Yi Lim2, Liang Qu1
1Department of Urology Monash Health Melbourne Victoria Australia.
BJUI compass
|August 19, 2024
概括
周围的阿尔法阻塞剂显著改善尿功能,减少前列腺活检后的急性尿. 这一元分析表明,常规使用α阻断剂可缓解活检后排泄并发症.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 排泄功能障碍是前列腺活检后的常见并发症,影响患者的发病率.
- 阿尔法抑制剂越来越多地用于预防这些副作用,但有效性的证据有限.
研究的目的:
- 系统地审查和分析术后阿尔法阻断剂在改善前列腺活检后空腔功能方面的疗效.
主要方法:
- 从1989年到2023年,主要数据库 (MEDLINE,Embase,PubMed) 进行了系统的文献搜索.
- 包括六项随机对照试验,涉及808名患者,将α阻断剂与对照剂进行比较.
- 关于国际前列腺症状评分 (IPSS),Qmax,空气后残留量 (PVR),急性尿 (AUR) 和生活质量 (QoL) 的数据被提取用于元分析.
主要成果:
- 阿尔法阻断剂的使用在IPSS,PVR,Qmax和QoL得分上显示了统计学上显著的改善.
- 在阿尔法阻塞剂组中,急性尿 (AUR) 的总体风险显著降低 (OR 0.22,CI 0.09-0.55,p=0.001).
- 异质性在各种结果中各不相同 (I2 = 0-86%).
结论:
- 术后的α阻塞剂在前列腺活检后增强尿功能方面发挥了潜在的作用.
- 可以考虑常规纳入α阻塞剂,以减少前列腺活检后与空白并发症相关的发病率.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
564
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
564
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
837
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
837
Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138


